AstraZeneca PLC $AZN Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 40.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,430 shares of the company’s stock after selling 23,337 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in AstraZeneca were worth $2,406,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AZN. Goldman Sachs Group Inc. increased its holdings in shares of AstraZeneca by 30.9% in the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after purchasing an additional 3,224,251 shares during the period. Valeo Financial Advisors LLC increased its stake in AstraZeneca by 14,797.3% in the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after buying an additional 2,307,047 shares during the period. American Century Companies Inc. raised its position in AstraZeneca by 406.9% during the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock worth $148,517,000 after buying an additional 1,621,974 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after acquiring an additional 1,605,133 shares in the last quarter. Finally, Boston Partners increased its stake in shares of AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after acquiring an additional 1,329,166 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Jefferies Financial Group began coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Up 1.0%

NASDAQ:AZN opened at $84.58 on Monday. The company has a market capitalization of $262.32 billion, a PE ratio of 31.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $86.57. The stock has a fifty day simple moving average of $81.41 and a 200-day simple moving average of $75.60. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.08 earnings per share. On average, equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.